Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial

Published:2023-10 Issue: Volume:64 Page:102140
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Song Joon Young^ORCID,Choi Won Suk,Heo Jung Yeon,Kim Eun Jin,Lee Jin Soo,Jung Dong Sik,Kim Shin-Woo,Park Kyung-Hwa,Eom Joong Sik,Jeong Su Jin,Lee Jacob,Kwon Ki Tae,Choi Hee Jung,Sohn Jang Wook,Kim Young Keun,Yoo Byung Wook,Jang In-Jin,Capeding Maria Z.,Roman François,Breuer Thomas,Wysocki Piotr,Carter Lauren,Sahastrabuddhe Sushant,Song Manki,D'Cor Naveena,Kim Hun,Ryu Ji Hwa,Lee Su Jeen,Park Yong Wook,Cheong Hee Jin,Philippot Agathe,Solmi Francesca,Ceregido Maria Angeles,Shim Byoung-Shik,Seo Sang Hwan,D'Souza Simone,Thaisrivichai Patchara,Carlos Josefina,Alberto Edison,Nitayaphan Sorachai,Ratanasuwan Winai,Mootsikapun Piroon,Chaiwarith Romanee,Chan Quang Luong,Karpenko Olena,Yurkiv Tatiana,Kutovyi Vitalii,Bartko Angela,Gyrina Olga,Barna Olga,Pugach Mykhailo,Thurlow Claire,Carson Simon,Smith Susan,Williams Mike,Hemi Senior Tiwini,Humphrey Tim,Sheahan Davitt,Park Hokeun,Lee Yoon Yeong,Kang Seung Gu

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review;Fiolet;Clin Microbiol Infect,2022

2. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-COV-2;Walls;Cell,2020

3. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines;Walls;Cell,2021

4. Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity;Morel;Vaccine,2011

5. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a randomised, placebo-controlled, observer-blinded phase 1/2 trial;Song;eClinicalMedicine,2022

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The gut microbiota modifies antibody durability and booster responses after SARS-CoV-2 vaccination;Journal of Translational Medicine;2024-09-06

2. A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates;Frontiers in Immunology;2024-07-16

3. Advances in virus-like particle-based SARS-CoV-2 vaccines;Frontiers in Cellular and Infection Microbiology;2024-06-26

4. Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults;Vaccines;2024-05-14

5. Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV;2024-03-14